Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Overview
Date Founded

1781

Headquarters

2-12-10 Nihonbashi,Chuo-Ku,Tokyo 103-8668

Type of Company

Public

Employees (Worldwide)

27.2K

Industries

Pharmaceuticals
IT Consulting & Services
Hospitals & Patient Services
Medical Support Services
Chemicals
Biotechnology

Company Description

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Executive Officer & Global General Counsel

Director Chief Medical & Scientific Officer

General Manager, Health Innovation Park-Shonan

President, Europe & Canada Business Unit

President, US Business Unit

President, Japan Pharma Business Unit

President, Global Oncology Business Unit

President, EUCAN Business Unit

Advisory Board

Former Chief Executive Officer at Eli Lilly & Company

Paths to Takeda Pharmaceutical Co., Ltd.
Potential Connections via
Relationship Science
You
Takeda Pharmaceutical Co., Ltd.
Owners & Shareholders
Details Hidden

NAM-J is an active, value-oriented manager with a global perspective and a medium- to long-term outlook. Their investment philosophy emphasizes multi-faceted research shared internationally throughout the group, and local expertise contributed by their overseas offices. Their strong research capabilities, supported and integrated globally by proprietary systems, include fundamental analysis, company visits, market research, credit analysis, macroeconomic projections and quantitative analysis. Their global asset allocation strategy is determined by an investment committee at the group level.The firm uses a variety of strategies including active, passive and active quantitative. Their funds are invested in domestic and global equity and fixed-income, as well as in Japanese money market instruments. The majority of their investments are in equity, complemented by a substantial minority of bonds and investments in private placement funds. The firm manages a range of Japanese ETFs including sector funds.NAM-J's investment process is team-based and combines bottom-up and top-down strategies, with a bias towards stockpicking.

Details Hidden

Mondrian is a long-term, team-based, value-oriented manager with an active style and a defensive philosophy. They invest in global equity and debt across market-caps.The firm focuses their equity investments on value stocks identified through inflation-adjusted discounted income stream analysis, paying particular attention to dividend yield. They seek to provide a rate of return greater than the client’s domestic rate of inflation and construct portfolios that preserve capital during protracted international market declines Their fixed-income investments target high inflation-adjusted income vehicles globally, utilizing their qualitative, quantitative, sovereign, and credit capabilities. They manage strategies in developed and emerging bond markets.Mondrian's investment managers are organized in teams focused on regions, sectors or asset classes while retaining individual accountability. Decisions are process-driven and based on internal research complemented by company visits.

Details Hidden

Causeway Capital Management (CCM) specializes in managing investments in international and global value equities. Their strategies include: international value equity, international value select, global value equity, emerging markets equity, international opportunities, global opportunities and global absolute return. In addition, CCM manages ADR, socially responsible and concentrated versions of some of their strategies. The strategies primarily invest in international and US equity securities using fundamental value and quantitative investment techniques. In the global absolute return strategy, the firm also uses leverage and total return equity swap agreements to take long and short positions in equity securities. CCM may also directly sell securities short in the global absolute return strategy.

Recent Transactions
Details Hidden

Shanghai Pharmaceuticals Holding Co., Ltd. purchases Techpool Bio-Pharma Co., Ltd. from Takeda Pharmaceutical Co., Ltd.

Details Hidden

Takeda Pharmaceutical Co., Ltd. purchases Shire Plc

Details Hidden

Grupo NC purchases Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. from Takeda Pharmaceutical Co., Ltd.

Transaction Advisors
Investment Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Pharmaceuticals International GmbH from Credit Suisse Group AG, aPriori Capital Partners LP, Coller Capital Ltd., Nordic Capital V Ltd., Avista Capital Partners, Nordic Capital VI Ltd., Coller International Partners IV LP, Coller International Partners V LP

Legal Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Shire Plc

Investment Advisor

Advised onCaraco Pharmaceutical Laboratories Ltd., Sun Pharmaceutical Industries Ltd. purchase URL Pharma, Inc. /Generic Business from Takeda Pharmaceutical Co., Ltd.

Legal Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Oncology Co.

Legal Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Pharmaceuticals International GmbH from Credit Suisse Group AG, aPriori Capital Partners LP, Coller Capital Ltd., Nordic Capital V Ltd., Avista Capital Partners, Nordic Capital VI Ltd., Coller International Partners IV LP, Coller International Partners V LP

Attorney

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Oncology Co.

Advisors & Consultants
Legal Advisor

Partner at Hogan & Lovells LLP

Advisor

Co-Founder at Outpost Medicine LLC

Legal Advisor

Managing Director & General Counsel at BDT Capital Partners LLC

Clients

The Bill & Melinda Gates Foundation was formed in 1997 as the William H. Gates Foundation. In 1999, the foundation was renamed the Bill & Melinda Gates Foundation. The Bill & Melinda Gates Foundation Trust was created in January 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation, which focused on improving global health. The foundation participates in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries. Through their partnerships in communities across the US, the Bill & Melinda Gates Foundation is committed to raising the high school graduation rate and helping all students, regardless of race or family income. The foundation is headquartered in Seattle, Washington.

Taisho Pharmaceutical Holdings Co. Ltd. engages in the management and administration of its group companies that manufactures and sells over-the-counter (OTC) drugs, foods, and other goods, etc. It operates through the following segments: Self-Medication and Prescription Pharmaceutical. The Self-Medication segment conducts research and development (R&D), manufacturing and sale of over-the-counter drugs, quasi-drugs, food, and general medical and hygiene supplies. The Prescription Pharmaceutical segment handles R&D, manufacturing, and sale of ethical drugs. It also provides the manufacture and sale of prescription pharmaceuticals; and businesses incidental or related thereto. The company was founded on October 3, 2011 and is headquartered in Tokyo, Japan.

Hikma Pharmaceuticals We are committed to improving people’s lives. Through our existing products and pending approvals across our markets, our aim is to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas. Our vision Our vision is to build Hikma into a world class and leading specialty pharmaceutical company, with presence across the globe. Through organic growth and by acquisitions which are aligned with our strategy, we will continue to develop the business and maintain the high standards of ethics and responsibility which are central to the way we operate.

Key Stats and Financials As of 2018
Market Capitalization
$3.67T
Total Enterprise Value
$4.76T
Earnings Per Share
$239.35
Revenue
$1.77T
Net Profit
$187B
EBITDA
$377B
EBITDAMargin
21.32%
Total Debt
$1.04T
Total Equity
$2.02T
Enterprise Value Sales
2.69x
Enterprise Value EBITDAOperating
12.61x
TEVNet Income
25.48x
Debt TEV
0.22x
Five Year Compounded Annual Growth Rate Of Revenue
2.6%
Three Year Compounded Annual Growth Rate Of Revenue
-0.14%
Investments
Details Hidden

Ovid Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing impactful medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Details Hidden

Cerevance LLC develops novel therapeutics for neurological and psychiatric disorders. The company is headquartered in Cambridge, MA.

Details Hidden

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Suppliers
Alnylam Pharmaceuticals, Inc. Medical Support Services | Wilmington, DE

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Aska Pharmaceutical Co., Ltd. Retail: Drug Stores | Tokyo, TY

ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import and export of pharmaceuticals,veterinary medicines,quasi-drugs,foods,and medical devices. It operates through the following business division: Research and Development. The Research and Development division provides new medicine in R&D system with a balanced combination of cutting-edge pharmaceutical technology and a long experience, to grow and expand persistently as a medium R&D company focusing on a specialized field. Its products include drugs for internal medicine; drugs for obstetrics and genecology; and drugs for urology. The company was founded by Yasohachi Yamaguchi on June 16, 1920 and is headquartered in Tokyo, Japan.

Medical & Biological Laboratories Co., Ltd. Medical Support Services | Nagoya, AI

Medical & Biological Laboratories Co., Ltd. engages in the research, development, manufacture and sale of biological products. It operates through the Reagents and Investment segments. The Reagent segment supplies, manufactures, and sells clinical reagents and research reagents, and its related equipment and instruments. The Investment segment deals with investments on bio-related enterprises and mediates technical partnership. The company was founded on August 23, 1969 and is headquartered in Nagoya, Japan.